Pembrolizumab biosimilar - Sandoz
Alternative Names: GME-751Latest Information Update: 14 Jun 2024
At a glance
- Originator Sandoz
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase I Malignant melanoma
Most Recent Events
- 15 May 2024 Phase-I clinical trials in Malignant melanoma (Late-stage disease) in Romania (IV) (NCT06153238)
- 29 Apr 2024 Phase-III clinical trials in Non-small cell lung cancer (Metastatic disease, Combination therapy, First-line therapy) in Georgia (IV) (NCT06159790)
- 07 Dec 2023 Sandoz plans a phase III trial for Non small cell lung cancer (Metastatic disease, First line therapy, Combination therapy)in February 2024 (NCT06159790)